SSShigeru Sato

Shigeru Sato

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shigeru Sato has a total of 92 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Genotype–Phenotype Correlations in RPGRIP1-Associated Retinal Dystrophy in a Nationwide Japanese Cohort

    by Kei Mizobuchi, Taiga Inooka, Takuya Aoki, Hazuki Anzai, Kaoruko Torii, Kazuki Hashimoto, Akiko Suga, Ryo Ando, Miki Hiraoka, Taro Kominami, et al.

  • Open Access

    Initial Response After Switching to Aflibercept 8 mg for Neovascular Age-Related Macular Degeneration

    by Chikako Hara, Satoko Fujimoto, Yoko Fukushima, Kaori Sayanagi, Kentaro Nishida, Kazuichi Maruyama, Shigeru Sato, Takatoshi Maeno, Kohji Nishida

    Objectives: This study aimed to assess the initial anatomical and functional outcomes of switching to aflibercept 8 mg in patients with neovascular age-related macular degeneration (nAMD) previously treated with anti-vascular endothelial growth factor (VEGF) therapy. Methods: Patients with nAMD previously treated with anti-VEGF drugs were switched to aflibercept 8 mg. Patients with any exudative changes (subretinal fluid [SRF], intraretinal fluid [IRF] or serous pigment epithelial detachment [sPED]) at the time of the first aflibercept 8 mg injection and whose dosing interval before and after switching did not differ by more than ±7 days were included. Best-corrected visual acuity (BCVA), central foveal thickness (CFT), and the presence of SRF, IRF, and sPED were evaluated before and after switching to aflibercept 8 mg. Results: A total of 102 eyes from 98 patients were included in the analysis. The drugs used prior to switching were faricimab in five eyes, brolucizumab in six eyes, and aflibercept 2 mg in 91 eyes, with a mean interval of 63.7 ± 20.0 days from the last pre-switch injection and 64.9 ± 20.1 days to the first post-switch visit. The CFT was significantly reduced from 272 ± 85 µm to 246 ± 79 µm (p < 0.0001). The BCVA remained unchanged at 0.27 ± 0.35 logMAR. During switching, SRF, IRF, and sPED were observed in 70, 24, and 38 eyes, respectively. At the post-switch visit, complete resolution of exudative changes was observed in 44% of eyes with SRF, 55% with IRF, and 29% with sPED. No ocular or systemic adverse effects were observed. Conclusions: As an initial response to switching to aflibercept 8 mg in a real-world setting, SRF and IRF completely resolved in approximately half of the patients, and sPED resolved in about 30% of cases.


  • Open Access

    Initial Response of Switching to Aflibercept 8 mg for Neovascular Age-Related Macular Degeneration

    by Chikako Hara, Satoko Fujimoto, Yoko Fukushima, Kaori Sayanagi, Kentaro Nishida, Kazuichi Maruyama, Shigeru Sato, Takatoshi Maeno, Kohji Nishida

    Objectives: To assess the initial anatomical and functional outcomes of switching to aflibercept 8 mg in patients with neovascular age-related macular degeneration (nAMD) previously treated with anti-vascular endothelial growth factor (VEGF) therapy. Methods: Patients with nAMD previously treated with anti-VEGF drugs were switched to aflibercept 8 mg. Patients with any exudative changes (subretinal fluid [SRF], intraretinal fluid [IRF], or serous pigment epithelial detachment [sPED]) at the time of the first aflibercept 8 mg injection, and whose dosing interval before and after switching did not differ by more than ±7 days, were included. Best-corrected visual acuity (BCVA), central foveal thickness (CFT), and presence of SRF, IRF, and sPED were evaluated before and after switching to aflibercept 8 mg. Results: A total of 102 eyes from 98 patients were included in the analysis. The drugs used prior to switching were faricimab in five eyes, brolucizumab in six eyes, and aflibercept 2 mg in 91 eyes, with a mean interval of 63.7 ± 20.0 days from the last pre-switch injection and 64.9 ± 20.1 days to the first post-switch visit. The CFT was significantly reduced from 272 ± 85 to 246 ± 79 (p<0.0001). The BCVA remained unchanged at 0.27 ± 0.35. During switching, SRF, IRF, and sPED were observed in 70, 24, and 38 eyes, respectively. At post-switch visit, complete resolution of exudative changes was observed in 44% of eyes with SRF, 55% with IRF, and 29% with sPED. No ocular or systemic adverse effects were observed. Conclusions: As an initial response to switching to aflibercept 8 mg in a real-world setting, SRF and IRF completely resolved in approximately half of the patients, and sPED resolved in about 30% of cases.


  • Vertical infantile nystagmus: Explanation of why the direction of nystagmus is vertical

    by Takao Imai, Kayoko Higashi-Shingai, Takeshi Morimoto, Shigeru Sato, Takefumi Kamakura, Yumi Ohta, Takashi Sato, Hidenori Inohara

  • Open Access

    Comparison of Loading Dose between Aflibercept and Faricimab for Neovascular Age-Related Macular Degeneration

    by Chikako Hara, Masaki Suzue, Satoko Fujimoto, Yoko Fukushima, Kaori Sayanagi, Kentaro Nishida, Kazuichi Maruyama, Shigeru Sato, Kohji Nishida

    Background: Recently, faricimab was approved as the new drug for neovascular age-related macular degeneration (nAMD). We lack the knowledge to choose between the existing drug and this new drug to use for treatment-naïve nAMD cases. In this study, we compared the functional and morphologic effects in loading dose between patients with treatment-naïve nAMD treated with either intravitreal aflibercept (IVA) or intravitreal faricimab (IVF) injection in a clinical setting. Method: This retrospective study included 30 eyes of 28 patients who started treatment with IVA between June and September 2022 and 30 eyes of 29 patients who were administered IVF between October 2022 and March 2023. All patients received three monthly IVA or IVF. The best corrected visual acuity (BCVA), central retinal thickness (CRT), and the proportion of eyes with residual exudative change at baseline and 1,2, and 3 months after initial treatment were compared between the groups. Results: The mean BCVA significantly improved from pre-treatment after the loading dose in the IVA group (0.46 ± 0.46–0.36 ± 0.37, p = 0.0047) but not in the IVF group (0.46 ± 0.41–0.44 ± 0.45, p = 0.60). The mean CRT significantly improved in both groups. The proportion of eyes with residual exudative change was greater in the IVF group than in the IVA group 2 months after the first treatment (p = 0.026). The analysis of cases that achieved complete resolution of exudative changes after the loading dose showed that the IVA group had a significant improvement in the BCVA, whereas the IVF group did not (p = 0.0047 and 0.20, respectively). Conclusions: Although both IVA and IVF significantly improved CRT, the BCVA improved significantly in the IVA group but not in the IVF group.


  • Open Access

    Two Japanese Families with Pigmented Paravenous Retinochoroidal Atrophy and HK1 Mutation: A Case Report

    by Shigeru Sato, Takeshi Morimoto, Takashi Fujikado, Sayaka Tanaka, Sou Sai, Motokazu Tsujikawa, Kohji Nishida

    Hexokinase 1 (HK1) gene is the cause of autosomal dominant retinitis pigmentosa (RP) 79. To date, only E874K mutation has been reported as the causative mutation in patients with nonsyndromic RP. As a Caucasian RP case with a pathological variant of HK1 exhibiting pigmented paravenous retinochoroidal atrophy (PPRCA) phenotype was recently reported, we reviewed RP79 cases in our Japanese RP cohort. Consequently, 2 Japanese patients, who were diagnosed with RP79 by genetic tests in our RP cohort, were included in this study. Patient 1 was a 60-year-old woman. Fundus examination revealed symmetrical donut-shaped retinal degeneration, with pigment deposition avoiding the macula. Moreover, degeneration extended in a peripheral direction along the vessels like a starfish, and degeneration was observed around the veins and arteries. Patient 2 was a 75-year-old man. Fundus examination revealed symmetric macula-avoiding donut-shaped retinal degeneration, with paravenous protruding degeneration along the blood vessels like in case 1. Both Japanese cases, which belonged to two separate families, had the same HK1 pathogenic mutation, with a phenotype of PPRCA. Furthermore, atrophy along retinal arteries was noted. Reviewing previous nonsyndromic RP79 cases revealed symptoms that are believed to be those of PPRCA. Ultra-widefield fundus imaging, especially ultra-widefield fundus autofluorescence, has been useful in detecting PPRCA. If these devices become widely available, more cases may be discovered in the future because PPRCA can be used as a clue to suspect RP79, and Sanger sequencing may be used to identify pathogenic mutations in HK1 at a lower cost and more easily than using whole-exome sequencing.


  • Open Access

    Comparison of Isolated or Combined Static Stretching and Foam Rolling on Knee Extensors’ Function

    by Kazuki Kasahara, Andreas Konrad, Riku Yoshida, Yuta Murakami, Shigeru Sato, Ryoma Koizumi, David G Behm, Masatoshi Nakamura

    Static stretching (SS), foam rolling (FR), and a combination of both are used as warm-ups for sports and training. However, no reports have compared or examined the warm-up effects of short-term interventions (i.e., 30-s). Therefore, this study was designed to compare and examine the effects of short-term SS, FR, and SS+FR on knee extensors. The dominant knee extensors of 14 male university students (22.0 ± 1.3 years old) were tested. Five conditions were randomized: 60-s SS, 60-s FR, 30-s SS+ 30-s FR, 30-s SS, and 30-s FR to examine differences in intervention method, duration, and combined. The measures were knee flexion range of motion (ROM), pain pressure threshold (PPT), tissue hardness, maximum voluntary contraction-isometric (MVC-ISO), and MVC-concentric (MVC-CON) torques, measured before and after the intervention. Knee flexion ROM (d = 0.40, d = 0.59, d = 0.54, d = 0.59, d = 0.52 respectively) and PPT (d = 0.77, d = 0.60, d = 0.90, d = 0.74, d = 0.52, respectively) were significantly increased (p < 0.01), and tissue hardness (d = -0.79, d = -0.63, d = -0.53, d = -0.59, d = -0.72, respectively) was significantly decreased (p < 0.01) in all conditions. However, MVC-ISO decreased significantly (p < 0.01) in the 60-s SS and 30-s SS conditions but did not affect MVC-CON in all conditions. The results of this study revealed that SS, FR, and SS+FR interventions for a short-term as a warm-up before exercise were effective in increasing ROM, PPT, and decreasing tissue hardness. However, SS intervention with more than 30-s on the knee extensors decreased muscle strength, so short-term FR intervention is recommended when the goal is to increase ROM while maintaining both MVC-ISO and MVC-CON torques. Similarly, a short-term FR intervention after a short-term SS can eliminate the effect of strength impairments.

  • Open Access

    Extensive Macular Atrophy with Pseudodrusen in a Japanese Patient Evaluated by Wide-Field OCTA

    by Shigeru Sato, Takeshi Morimoto, Takashi Fujikado, Sayaka Tanaka, Motokazu Tsujikawa, Kohji Nishida

    Extensive macular atrophy with pseudodrusen (EMAP) is a relatively newly proposed clinical entity that was first reported in 2009. Although no definitive diagnostic criteria have been defined, characteristic findings can distinguish it from other diseases, especially dry age-related macular dystrophy (AMD). Herein, we present the case of a patient with EMAP who underwent a comprehensive ophthalmic examination and whole-exome sequencing (WES). A 72-year-old Japanese man complained of progressive visual impairment in his right eye and nyctalopia. Ophthalmic examination revealed that the best-corrected visual acuity (BCVA) in decimal units was 0.08 on the right and 0.8 on the left. Fundoscopy and fundus autofluorescence (FAF) revealed well-demarcated symmetrical macular atrophy, with a vertical axis larger than the horizontal axis, which reached the vascular arcade inferiorly and exceeded it superiorly. Pseudodrusen were widespread throughout the retina in both eyes. Paving-stone degeneration was not observed in the extreme periphery of either eye. Seven months later, his left BCVA decreased to 0.3 without major changes on multimodal imaging. Based on the above findings, we diagnosed EMAP. Wide-field optical coherence tomography angiography (OCTA) showed no significant changes in the retinal vessels, but the density of choroidal vessels was reduced in the degenerated areas. We thought that this finding suggests that EMAP originates between the deep retina and choroid. WES did not reveal any candidate mutations in known pathogenic genes. To the best of our knowledge, this is the first report of a Japanese patient with EMAP, and no data for analysis of wide-field OCTA or equatorial OCT images of EMAP cases have been found in previous reports. EMAP is not well recognized in Asia and may be incorrectly diagnosed as dry-type AMD. EMAP should be included in the differential diagnosis of dry AMD, and this may lead to more Asians being diagnosed with EMAP in the future.


  • Embedding Technique versus Conventional Internal Limiting Membrane Peeling for Lamellar Macular Holes with Epiretinal Proliferation

    by Masanori Kanai, Susumu Sakimoto, Shizuka Takahashi, Kentaro Nishida, Kazuichi Maruyama, Shigeru Sato, Hirokazu Sakaguchi, Kohji Nishida